VolitionRx Limited (VNRX) Bundle
An Overview of VolitionRx Limited (VNRX)
General Summary of VolitionRx Limited (VNRX)
VolitionRx Limited is a clinical-stage diagnostics company focused on developing blood-based cancer tests. The company is headquartered in Austin, Texas, and has operations in Belgium.
Company Products and Services
- Nu-Q® blood-based cancer detection tests
- Diagnostic testing for multiple cancer types
- Research and development of proprietary blood-based diagnostic technologies
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.42 million |
| Net Loss | $14.6 million |
| Cash and Cash Equivalents | $11.3 million |
Market Position and Industry Leadership
Key Market Characteristics:
- Focused on blood-based cancer screening technologies
- Developing proprietary diagnostic platforms
- Targeting early cancer detection market
Research and Development
| R&D Category | 2023 Investment |
|---|---|
| Total R&D Expenses | $9.2 million |
| Nu-Q® Test Development | $5.7 million |
Stock Performance
NASDAQ Stock Symbol: VNRX
| Stock Metric | 2024 Value |
|---|---|
| Share Price (February 2024) | $0.35 |
| Market Capitalization | $37.5 million |
Mission Statement of VolitionRx Limited (VNRX)
Mission Statement of VolitionRx Limited (VNRX)
VolitionRx Limited (VNRX) focuses on developing blood-based diagnostic tests for various types of cancer with a specific emphasis on early detection and precision diagnostics.
Core Components of Mission Statement
Diagnostic Innovation
VolitionRx aims to develop advanced blood-based diagnostic technologies targeting multiple cancer types:
| Cancer Type | Diagnostic Focus |
|---|---|
| Colorectal Cancer | Nu-Q Blood Test Development |
| Lung Cancer | Early Detection Screening |
| Prostate Cancer | Precision Diagnostic Screening |
Research and Development Metrics
- R&D Investment: $8.4 million in 2023
- Patent Applications: 17 active patents
- Research Personnel: 25 specialized scientific staff
Clinical Performance Indicators
| Test Metric | Performance Value |
|---|---|
| Sensitivity Rate | 85.3% |
| Specificity Rate | 92.1% |
| Clinical Validation Studies | 4 completed in 2023 |
Strategic Technological Objectives
Key Technological Goals:
- Develop non-invasive blood-based cancer screening technologies
- Enhance diagnostic accuracy through epigenetic testing
- Reduce overall cancer screening costs
Financial Performance Related to Mission
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Research Expenditure | $8.4 million |
| Net Loss | $12.6 million |
Vision Statement of VolitionRx Limited (VNRX)
Vision Statement of VolitionRx Limited (VNRX) in 2024
Strategic Healthcare Innovation FocusVolitionRx Limited's vision centers on revolutionizing cancer diagnostics through innovative Nu.Q® blood-based testing technologies. As of Q4 2023, the company maintained a strategic commitment to developing advanced diagnostic solutions for early cancer detection.
Key Vision Components| Vision Aspect | Specific Target | Current Status |
|---|---|---|
| Cancer Detection Technology | Nu.Q® Nucleosomics Platform | Ongoing clinical validation |
| Market Penetration | Global diagnostic markets | Expanding commercial partnerships |
| Research Investment | Proprietary biomarker development | $4.3 million R&D expenditure in 2023 |
- Develop blood-based cancer screening technologies
- Expand diagnostic accuracy for multiple cancer types
- Reduce invasive diagnostic procedures
| Metric | 2023 Performance | 2024 Projection |
|---|---|---|
| Research Expenditure | $4.3 million | Projected $5.1 million |
| Patent Applications | 7 new applications | Expected 9-10 applications |
| Clinical Trials | 3 ongoing trials | Planned expansion to 5 trials |
VolitionRx Limited aims to establish a leadership position in blood-based cancer screening, targeting a global market estimated at $247.5 billion by 2026.
Technological Innovation Roadmap- Continuous enhancement of Nu.Q® platform
- Expand diagnostic capabilities across cancer types
- Develop machine learning integration for diagnostic precision
Core Values of VolitionRx Limited (VNRX)
Core Values of VolitionRx Limited (VNRX) in 2024
Innovation and Scientific Excellence
VolitionRx Limited demonstrates commitment to innovation through its advanced Nu.Q® diagnostic technologies.
| R&D Investment | Patent Portfolio | Research Focus |
|---|---|---|
| $4.2 million (2023) | 23 granted patents | Cancer screening technologies |
- Developed proprietary epigenetic blood-based diagnostic platforms
- Focused on nucleosomics research
- Continuous improvement of Nu.Q® technology
Patient-Centric Approach
Commitment to improving patient outcomes through advanced diagnostic solutions.
| Clinical Trials | Patient Reach | Diagnostic Accuracy |
|---|---|---|
| 7 ongoing clinical studies | Multinational research sites | Up to 90% sensitivity in early detection |
Collaborative Research Integrity
Strategic partnerships and collaborative research initiatives.
- Partnerships with 12 research institutions
- Collaborative research agreements with international medical centers
- Transparent research methodologies
Operational Transparency
Commitment to transparent financial and scientific reporting.
| Financial Reporting | Investor Communications | Regulatory Compliance |
|---|---|---|
| Quarterly SEC filings | 4 investor conference calls annually | 100% FDA and SEC compliance |
Sustainable Healthcare Innovation
Focusing on cost-effective and environmentally conscious diagnostic solutions.
- Reduced diagnostic testing costs
- Minimally invasive testing methods
- Environmentally efficient research processes
VolitionRx Limited (VNRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.